This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (29)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Kenneth L. Herrmann, MD; Scott B. Halstead, MD; Ned H. Wiebenga, MD

JAMA. 1982;247(2):193-196.

Abstract
A comparative field trial of three live, attenuated rubella virus vaccines (Cendehill, HPV-77 DE-5, and HPV-77 DK-12) was initiated in 1969 on the islands of Kauai and Hawaii in the state of Hawaii. Following initial seroconversion rates of more than 98%, periodic serological testing of the study population was conducted to assess the durability of vaccine-induced immunity. In February 1980, ten years after the initiation of the study, 741 of the 5,153 original susceptible vaccinees were still enrolled in the study. After a drop of approximately 50% in mean hemagglutination-inhibition (HI) titer for each of the vaccine groups during the first four years following vaccination, the HI titer levels for all three groups have been generally stable between years 4 and 10. The frequency of reversion to an HI titer of less than 10 has remained less than 0.5% per year. A measurable HI antibody level has persisted in more than 97% of all vaccinees over the ten-year period. This study indicates that when potent rubella vaccine is administered properly, a high seroconversion rate and a high rate of antibody persistence should be expected.

(JAMA 1982;247:193-196)

Author Affiliations
From the Perinatal Virology Branch, Virology Division, Center for Infectious Diseases, Centers for Disease Control, Atlanta (Dr Herrmann), the Department of Tropical Medicine and Medical Microbiology, University of Hawaii School of Medicine, Honolulu (Dr Halstead), and the Division of Epidemiology, State Department of Health, Honolulu (Dr Wiebenga).

Footnotes
Reprint requests to the Viral Diseases Division 7-240, Center for Infectious Diseases, Centers for Disease Control, Atlanta, GA 30333 (Dr Herrmann).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Duration of Humoral Immunity to Common Viral and Vaccine Antigens
Amanna et al.
NEJM 2007;357:1903-1915.
ABSTRACT | FULL TEXT  

Rubella Antibody Persistence After Immunization: Sixteen-Year Follow-up in the Hawaiian Islands
Chu et al.
JAMA 1988;259:3133-3136.
ABSTRACT  

Some Current Issues Relating to Rubella Vaccine
Preblud
JAMA 1985;254:253-256.
ABSTRACT  

Rubella Prevention: Recommendation of the Immunization Practices Advisory Committee
ANN INTERN MED 1984;101:505-513.
ABSTRACT  

Serological Response to Rubella Revaccination
Serdula et al.
JAMA 1984;251:1974-1977.
ABSTRACT  

The Opportunity and Obligation to Eliminate Rubella From the United States
Orenstein et al.
JAMA 1984;251:1988-1994.
ABSTRACT